Another PML case associated with Raptiva

Executive Summary

A second case of progressive multifocal leukoencephalopathy associated with Raptiva (efalizumab) prompts Genentech to issue another Dear Healthcare Provider letter to dermatologists and neurologists. The current case caused the death of a 73-year old woman treated for four years with Raptiva for chronic plaque psoriasis, and follows a similar case in October. Genentech says it believes the drug likely increases the risk of PML and that prolonged exposure to Raptiva and older age may further increase this risk. The drug's labeling was updated in October and FDA has asked the firm to submit a Risk Evaluation and Mitigation Strategy (1"The Pink Sheet" DAILY, Oct. 17, 2008)